Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention

NCT06281834 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT06281834
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06281834 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 1
Overall status
Recruiting
Start date
November 15, 2024
Completion date
June 1, 2027
Enrollment
25 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

latent tuberculosis, pediatric hiv infection